Can Invega Sustenna (paliperidone palmitate) cause erections or priapism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Invega Sustenna Cause Erections?

Invega Sustenna (paliperidone palmitate) does not cause erections; rather, it is associated with erectile dysfunction and, rarely, priapism (prolonged, painful erections lasting >4 hours). The medication's alpha-adrenergic blocking effects can lead to priapism, which is a medical emergency requiring immediate intervention 1.

Understanding the Sexual Side Effects

Erectile Dysfunction (More Common)

Invega Sustenna commonly causes erectile dysfunction, not normal erections. In clinical trials, erectile dysfunction occurred in 2.5% of males during the open-label phase 1. This occurs through:

  • Hyperprolactinemia: The medication significantly elevates prolactin levels (mean increase from 14.6 ng/mL to 32.8 ng/mL in males), which suppresses testosterone and impairs erectile function 1
  • Alpha-adrenergic effects: These interfere with normal erectile mechanisms
  • During the 15-month double-blind phase, 7.1% of males experienced prolactin-related adverse reactions including erectile dysfunction and decreased libido 1

Priapism (Rare but Serious)

Priapism is a medical emergency defined as a persistent, painful erection lasting >4 hours unrelated to sexual stimulation 2. While no cases occurred in Invega Sustenna clinical trials, priapism has been reported with oral paliperidone in postmarketing surveillance 1.

Immediate Management Algorithm for Priapism:

  1. If erection lasts >4 hours: Go to emergency department immediately 1
  2. Ischemic priapism (rigid, painful penis):
    • This is an emergency requiring treatment within 4-6 hours to prevent permanent damage 2, 3
    • Treatment involves intracavernosal phenylephrine injection 3
    • If untreated >6 hours, permanent erectile dysfunction may result 4
  3. Severe cases may require surgical intervention 1

Clinical Context

A case report documented recurrent priapism in a 51-year-old male approximately 1 month after starting paliperidone palmitate, requiring intracavernous adrenaline injection and corpus cavernosum drainage 5. The priapism recurred one week after stopping the medication, highlighting the potential for delayed effects.

Key Clinical Pitfalls

  • Do not confuse erectile dysfunction with priapism: Erectile dysfunction (inability to achieve/maintain erection) is common; priapism (prolonged unwanted erection) is rare but dangerous
  • Monitor for hyperprolactinemia: Check prolactin levels if sexual dysfunction develops, as 53.3% of males experienced prolactin elevations above reference range 1
  • Educate patients: They must seek immediate care for any erection lasting >4 hours 1
  • Consider medication change: If erectile dysfunction or priapism occurs, switching to an alternative antipsychotic (such as olanzapine, as used successfully in the case report) may be necessary 5

References

4
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

5
Research

Recurrent Priapism Due to Paliperidone Palmitate Use: A Case Report.

Psychiatry and clinical psychopharmacology, 2022

Related Questions

What is the appropriate dosing regimen for Invega Sustenna (paliperidone palmitate) in an adult patient with schizophrenia who has not previously received paliperidone?
What is the correct dosing schedule for Invega (paliperidone palmitate) and how should I manage persistent hallucinations, crying, and sadness while on a 156 mg dose?
When does the peak plasma concentration occur after an Invega (paliperidone palmitate) injection?
What is the appropriate next dose of Invega (paliperidone palmitate) after a 234 mg injection following an initial 156 mg loading dose?
For a patient receiving Invega LAI (paliperidone palmitate), how soon after a 30‑day interval can the next injection be administered?
How should a patient with a peripheral capillary oxygen saturation (SpO₂) of 7% be managed?
In a patient with vasomotor symptoms, mildly elevated AST and no advanced liver disease, who agrees to limit alcohol intake, should I recommend transdermal estradiol gel (Estrogel) as therapy?
In a patient with Parkinson’s disease taking Carbidopa‑Levodopa 25‑100 mg tablets, 0.5 tablet by mouth three times daily, who is now experiencing involuntary movements, should the levodopa dose be increased?
Are hydrocodone/acetaminophen (Norco), pregabalin (Lyrica), and prednisone safe to prescribe for a patient taking clonidine, paroxetine, and erenumab (Emgality)?
Which laboratory test assesses immunity to hepatitis B after vaccination?
Please provide a primary care SOAP note for a 30‑45‑year‑old adult presenting with a 5‑day history of productive cough, sore throat, low‑grade fever, nasal congestion, mild chest discomfort, no shortness of breath, no hemoptysis, no chronic lung disease, non‑smoker, and up‑to‑date immunizations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.